Genomic studies have identified recurrent somatic mutations in acute leukemias. However, current murine models do not sufficiently encompass the genomic complexity of human leukemias. To develop preclinical models, we transplanted 160 samples from patients with acute leukemia (acute myeloid leukemia, mixed lineage leukemia, B-cell acute lymphoblastic leukemia, T-cell ALL) into immunodeficient mice. Of these, 119 engrafted with expected immunophenotype. Targeted sequencing of 374 genes and 265 frequently rearranged RNAs detected recurrent and novel genetic lesions in 48 paired primary tumor (PT) and patient-derived xenotransplant (PDX) samples. Overall, the frequencies of 274 somatic variant alleles correlated between PT and PDX samples, although the data were highly variable for variant alleles present at 0-10%. Seventeen percent of variant alleles were detected in either PT or PDX samples only. Based on variant allele frequency changes, 24 PT-PDX pairs were classified as concordant while the other 24 pairs showed various degree of clonal discordance. There was no correlation of clonal concordance with clinical parameters of diseases. Significantly more bone marrow samples than peripheral blood samples engrafted discordantly. These data demonstrate the utility of developing PDX banks for modeling human leukemia, and emphasize the importance of genomic profiling of PDX and patient samples to ensure concordance before performing mechanistic or therapeutic studies.
INTRODUCTION
Acute myeloid and lymphoid leukemias are heterogeneous diseases with subsets having dismal prognosis. 1 Successful development of novel targeted therapies critically depends on the availability of genetically annotated preclinical animal models, which may be informative for initiation of clinical trials and understanding resistance to novel targeted therapeutics. Currently, the choices for preclinical animal models are: genetically engineered mouse models (GEMMs) of human leukemias or patient-derived xenotransplant (PDX) models. Advantages of GEMMs include their defined genetics and scalability. Unfortunately, GEMMs do not cover much of the spectra of genetic lesions that occur in patients. 2 The potential advantage of PDX models is the genetic diversity that is found in patients and that is likely to be important for preclinical assessment of therapies targeting specific genetic lesions. PDX models are widely used for studying the biology of diseases and testing potential compounds, however it remains unclear the extent to which PDXs faithfully maintain the genetic and genomic complexity seen in primary patient samples. [3] [4] [5] [6] Large-scale sequencing of genomes and whole exomes in samples from newly diagnosed and relapsed leukemia patients has demonstrated recurrent genetic aberrations that are, in some cases, specific for disease lineage. Sequencing has also revealed that, in some cases, the mutant alleles and their frequencies differ between samples from newly diagnosed and relapsed acute leukemia patients. 7 These findings support the concept of genetic drift and that tumorigenesis is a continuous process in which mutations are acquired sequentially. At any point in the process, a founding and minor clone(s) may coexist and the latter may eventually become dominant. Therefore, acute leukemia may be initiated as a monoclonal disease and become polyclonal after acquiring additional genetic lesions. [8] [9] [10] Recently, the usefulness of PDX models for preclinical assessment has been questioned because of the clonal selection that occurs after transplantation of primary tumor (PT) samples into immunodeficient mice. [11] [12] [13] The aims of this study were: (1) to establish a collection of engraftable and genomically annotated patient samples; (2) to assess which leukemia relevant mutant alleles engraft in mice with frequency similar to that observed in PT samples.
MATERIALS AND METHODS

Patient samples and transplantations
Acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL) patient samples were acquired from the Hematologic Oncology Tissue Bank at Memorial Sloan Kettering Cancer Center; T-cell ALL (T-ALL) patient samples were acquired from the Eastern Cooperative Oncology Group study and Columbia University Hospital under Institutional Review Board-approved protocols. All patients provided written informed consent. Samples were intravenously injected into 1-6 (on average two) irradiated (200 RADs) NSG mice at 10 14 For amplicon-sequencing gDNA was isolated from seven available and not related PDX samples, selected genomic regions were amplified using microdroplet-PCR followed by illumina sequencing. 15 Excluding PE100 reads that align to mouse genome (mm9) in PDX samples resulted in loss o0.6% reads, which was considered not to affect VAF and therefore disregarded. 16 For detailed description please refer to supplemental methods.
RESULTS
Acute leukemia patient samples robustly engraft in NSG mice
We transplanted 160 patient samples, balanced by disease lineage, status and patient age, into NSG mice, Supplementary 17 or were predicted to alter protein function on tumor suppressor genes were designated as somatic variant alleles (SVA); other genomic variants were designated as variants of unknown significance (VUS).
14,18 VUS were enriched in SNPs and were used in analyses independently.
We detected sequences corresponding to fusion RNA of known RE in 23 PT samples:
, MYH11-CBFB (1) and TAL1 internal rearrangements (1). In three B-ALL and two T-ALL samples we detected multiple RE. In three PT and matched PDX samples, we detected sequences corresponding to likely novel fusion proteins, such as RB1-RCBTB2 (1), PAX5-FLI1 (1) and PAX5-MSI2 (1).
The most frequent substitutions, insertions and deletions, and CNA detected were: CDKN2A (28), CDKN2B (22) deletions; TP53 (12), FLT3 (short nucleotide variances and internal tandem duplication (ITD) (11), NOTCH1 (11), WT1 (11), NRAS (10), PTEN (10), PTPN11 (9), NPM1c (7), JAK1/2/3 (6), KRAS (6), DNMT3A (6), IDH1/2 (5), and ASXL1 (5), Table 2 and Supplementary Table 6 ; similarly to previously reported. 10, 19 All mutations detected in PT using clinical tests were also confirmed by FoundationOne Heme. AML  56  25  19  9  2  1  8  48  48  45  24  7  9  5  MLL  2  1  1  1  1  2  2  1  1  B-ALL  32  15  15  2  10  22  25  24  15  9  T-ALL  70  42  4  24  32  33  5  48  48  43  5  Total  160  83  39  11  2  25  51  104  5  123  119  83  7 ) but not uniform data, suggesting that the SVAF obtained from a single method should be considered to be used with a wider s.d., than calculated using the variance and depth-coverage from the single method, Figure 1c .
To enumerate the increase of SVAF in PDX samples, we measured a distance deviation (DD) between expected SVAF (PDX = PT) and measured SVAF values, Figure 2a . DD distributions between measured and expected VAF values was significantly larger for somatic than VUS (D K − S = 0.29, P o10 − 4 ). Histogram presentation of DD showed that VUS have a monomodal distribution with 91% values o 10%, whereas SVAF have a bimodal distribution, with only 68% values in same range; and 
Abbreviations: AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoblastic leukemia; CAN, copy number alterations; MLL, mixed lineage leukemia; PDX, patient-derived xenotransplant; PT, primary tumor; RE, chromosomal rearrangements; SNV, short nucleotide variances; T-ALL, T-cell ALL. Detection of SNV; CNA; and known or likely (computationally predicted in frame) RE in 18 AML, 23 B-ALL, 2 MLL, and 24T-ALL PT and PDX samples, across four leukemia lineages. 'PT'-number of PT samples in which a lesion was detected.
28% (vs 7% for DD VUS
) in the 15-50% range, black bars represent ranges in Figure 2b . This distribution pattern confirms that VUS are less variable and are likely present in all cells of PT samples. Suggesting that SVAF mark the clones that change in frequency relative to the original bulk tumor. To assess what SVAF values are the most variable between PT and PDX samples we subdivided them into three groups 0-10%, 10-30% and 30-100% by PT values. SVAF of the 10-30% group was the most variable 48% in 15-50% DD window, whereas 0-10 and 30-100% groups showed 17 and 18% DD variability, respectively, Figure 2c . Moreover, in SVAF of the 10-30% group, 24 of 53 (45%) values changed greater than twofold in PDX as compared with PT samples.
Overall, both SVAF and VUS values significantly correlate between PT and PDX samples. SVAF have higher variability between PT and PDX samples, which suggests clonal changes in PDX samples. The most variable SVAF values were in the 'minor clone mutation' range (0-10%), likely representing high s.d. of detection. However, close to half of SVAF marking 'major clones' contributes to the observed clonal changes.
Concordance of leukemia drivers within individual patients and PDX pairs It has been previously reported that the clonal composition of PDX samples may change after engraftment in non-irradiated immunodeficient recipient mice. 11 We speculated that if genetic mutations instruct clonal selection, the clones must possess at least one genetic variant that provides a competitive advantage over the founding clone in the tumor. Data plotted in Figure 2b suggest that SVA are more likely to contribute to clonal discordance (CD), as previously suggested. 20 Scatter plots of SVAF values for individual PT-PDX pairs can be classified into two groups. samples. First, we assessed CC of PT-PDX using the detection of SVAF ⩾ 10% in both PT and PDX samples, as previous publications indicated that an SVAF of o10% has a high false discovery rate.
11
One or more SVA were missing in four PDX samples, four PT samples or seven paired PT-PDX, Figure 3c . Second, we measured CD on the basis of a greater than twofold change in the values of SVAFs in the 10-90% range. Nineteen PT-PDX pairs had at least one variant allele that changed frequency greater than twofold, Figure 3d . Overall, 24 of 48 PT-PDX pairs were considered CC using two criteria: less than twofold change for SVAF and presence of all SVAF410%, Supplementary Table 8 .
Concordantly engrafting PT samples did not differ from discordantly engrafting PT samples in latency or engraftment levels in murine BM or spleen tissues. There was no correlation between concordance of engraftment and disease lineage, disease status (if all disease lineages were analyzed together), patient age or future relapse or adverse clinical outcome. Deletions within CDKN2A/B loci or known rearrangements did not correlate with CD. At the same time, known RE and CDKN2A/B loss appear to be mutually exclusive (Fisher, P o10 Tables 2 and 9 .
Nevertheless, 11 of 14 PDX that arose from PT BM samples were CD as compared with only 8 of 26 PDX that arose from PT peripheral blood samples (Fisher, P o0.05). PT samples that produced CC PDX on average had an insignificantly higher mean of blast content 72% compared with 61% of samples producing CD PDX. Therefore, it is plausible that the sample tissue and tumor burden may contribute to the observed CD, Supplementary Table 8 .
Stable variant alleles in clonally discordant samples Sequencing of diagnostic (D) and relapsed (R) PT 017 along with four PDX samples (017D_PDX15, 017DPDX16, 017D_PDX17, 017 R_PDX210), identified that six samples carry an MLL-AF9 translocation, PTPN11
G503A , and combinations of ECT2L
R852Q
, NRAS G12S and FLT3-ITD, Figure 4 . PT 017D, carried only MLL-AF9, ECT2L R852Q and PTPN11 G503A ; three PDX showed additional NRAS G12S , and 017D_PDX16, 017D_PDX17 showed additional variant alleles of FLT3-ITD (all o10%). It is unlikely that the same mutations occurred in two or three independent mice; more likely, these mutations already existed in 017D under the detection limit. Sequencing of PT 017R detected MLL-AF9, ECT2L R852Q ,
PTPN11
G503A , FLT3-ITD and NRAS
G12S
. However, the VAF
PTPN11
decreased from 23% in 017D to 2% in 017R and the similarly VAF FLT3-ITD increased from 'not detectable' to 14%; VAF NRAS in 017R was 2%, similar to the range detected in 017D_PDX15, 017D_PDX16 and 017D_PDX17. We conclude that it is likely that this AML sample at diagnosis had at least three sub-clones carrying MLL-AF9 and ECT2L R852Q and each was uniquely marked with (1) PTPN11 G503A , (2) FLT3-ITD and (3) NRAS G12S . In the relapsed sample, the clone (3) marked with NRAS G12S did not change frequency; it was minor and remained the minor clone. The clone (2) marked with FLT3-ITD expanded from a minor to a major clone. The clone (1) marked with PTPN11 G503A decreased from a major to a minor clone. Although PDX and PT samples demonstrated some variability in SVAF, overall, the PDX samples proportionally represented PT samples. As MLL-AF9 and ECT2L
R852Q were detected in all samples at similar levels, there is no basis to exclude any of these samples from testing therapeutics targeting either of these mutations. 017D may also be considered for experiments targeting PTPN11 G503A , and 017R for experiments targeting FLT3-ITD. This observation led us to assess not the clonal concordance of an individual PT-PDX pairs, but rather consistency of engraftment of individual allele across multiple PT-PDX pairs.
Correlation of allele frequencies of somatic variance between PT and PDX samples At lastly, we assessed whether variation of SVAF values between PT and PDX samples might be influenced by annotated gene function. We plotted the distribution of DD means for the recurrent (n ⩾ 2) 30 genes. We used the mean DD of all SVAFs (12.7%), as a threshold for classification, Figure 5a , Supplementary Table 10. SVAFs for 18 recurrent genes demonstrated mean DD o12.7% and therefore were considered similar between PT and PDX samples, Figure 5b, supplementary figure 4A . These are the mutations in genes that are likely either initiating events in leukemia pathogenesis, such as DNMT3A, PTPN11, WT1, FBXW7 and RUNX1, [22] [23] [24] [25] or do not influence engraftment in mice. In reviewing a similar group, we found that those whose variant allele values were similar between PT and PDX samples were also present on average in 60 ± 30% of concordant samples, Supplementary Table  10 . Overall, in the similar group, 6 of 18 genes, such as RUNX1, APC, ATM and IKZF1, were exclusively, whereas FBXW7 and WT1 were predominantly found in concordant samples.
SVAF for 12 genes demonstrated a mean DD 412.7% and therefore were designated as divergent between PT and PDX samples, Figure 5c, supplementary figure 4B, Supplementary Table 10 . These mutations may occur at later stages of leukemogenesis and may be present in only a fraction of leukemia cells and/or affect engraftment in mice (such as NPM1, MLL2, IDH1/2 and TET2 22, 26 ). In the divergent group, 8 of 12 genes, such as STAG2, MLL2, PAX5, TET2 and CEBPA, were exclusively, whereas NPM1, TP53 and IDH2 were predominantly found in the discordant samples. Together, alleles whose variances were divergent between PT and PDX samples were present on average in 80 ± 20% of discordant samples, Supplementary Table 10. Our data suggest that studies of the divergent alleles in xenotransplant settings will require rigorous genomic testing of PDX samples to ensure the presence of the studied allele at the expected frequency to draw any conclusions.
DISCUSSION
Individual PDX models are currently de facto standards in studying the biology of diseases and responses to novel therapeutics, often without extensive genomic characterization. [27] [28] [29] We established a resource of 119 PDX samples that can be serially xenotransplanted, 65 of which were annotated for genetic lesions relevant for hematologic malignancies for preclinical assessment of targeted therapeutics, Tables 1 and 2 . Currently, mouse genetic models provide a restricted set of leukemia models. For instance, majority of effort was focused on generating MLL-fusion; IDH1/2; FLT3-ITD; TET2 and DNMT3A-mediated AML. 2 Although these mutations are present in a significant portion of human leukemias, modeling of human leukemias bearing mutations for instance WT1, PTPN11 or PHF6 was rather limited. 30 It has been shown that for some B-ALL samples, all genetic variations observed in the PDX samples are already present in the patient sample at low levels. 31 Recent genomic characterization also raises a concern that PDX samples may not truthfully recapitulate clonal hierarchy of AML patient samples and may lead to changes in SVAF of targetable alleles when transplanted into non-irradiated recipient mice. 11 If PDX are a mixture of leukemia and either normal hematopoietic cells of different lineages or pre-leukemic HSC and their progeny, the sequencing readout may identify pre-leukemic VAF at the same frequency as detected in PT samples. These complexities need to be taken into account when tracking VAF in patient leukemia and PDX models as well as of host mouse strain, which can also influence engraftment of particular hematopoietic lineages. 32, 33 Targeted sequencing coupled with manual curation allows exclusion of false variants that result from low-quality alignment, from lowquality reads or from belonging to noisy genomic regions. 34 This is one of the benefits of targeted sequencing as manual curation of the whole exome or genome variants is likely to be overly laborious. On the other hand, not having manual curation may yield to variant alleles with unknown relevance.
In our data, SVAF correlated between PT and PDX samples with a modest mean increase in SVAF values in PDX samples. At the same time, 45% of SVAFs whose values were in the 10-30% range in PT samples changed greater than twofold in PDX samples. Although the variability in the 0-10% range may be attributed to both biological diversity and technical variability, the variation in the 10-30% range is most likely due to CD between PT and PDX samples, Figure 2b . Using defined parameters (floor = 10%, ratio ⩾ 2), 
G503A
, filled green triangle. Three PDX samples originated from 017D had an additional NRAS G12S (filled orange squares); two PDX samples had an additional FLT3-ITD (filled purple circles). We hypothesized that 017D had these two additional SVAF under detection limit (empty circle and square). Targeted sequencing of 017 relapse (R) identified all five alleles MLL-AF9, ECT2L
R852Q , PTPN11
, NRAS G12S and FLT3-ITD. It is likely that two clones uniquely marked with PTPN11
G503A and FLT3-ITD changed their frequencies. The clone marked with NRAS G12S was a minor clone and remained a minor clone. Although PTPN11 G503A and FLT3-ITD alleles were changing frequencies and NRAS G12S allele was always o10%, MLL-AF9 and ECT2L R852Q alleles did not change frequency.
we classified 24 of 48 PT samples as engrafting clonally concordantly. We observed that in five out of seven (71%) CC pairs, staining with CD34/CD38 antibodies produced a similar pattern in PT-PDX pairs. All three clonally discordant cases produced engraftment with very difference CD34/CD38 patterns. These data could be further used as a rough and quick assessment if PDX recapitulates original PT sample, as in 80% of cases immunophenotypic and genetic assessment of PT-PDX concordance matched, Supplementary Table 11 . We found that technical issues such as sample tissue or blast percentage might influence the classification of CC, Figures 3c and d. For instance, PT BM samples produced significantly more CD PDX possibly due to contamination of BM cells by stromal and/or fat cells, which may influence VAF. Some differences can be observed between our and previously published studies. 11 Such as we report that 50% of PT samples engraft clonally concordantly. We verified the lineage of the engrafted PDX by FACS and manually curated the variant alleles, which may partially explain some of the observed differences. We believe it is important to control for normal hematopoietic component (particularly T-cell) reconstitution in PDX samples, as hematopoietic cells engraft along with leukemia cells and can dilute 'minor clone' SVAF while leaving SVAF that occurred in stem cells unchanged. 22 For instance, in five samples, the mutant DNMT3A allele was within the 43-51% range. It has been reported that DNMT3A mutation is one of the early mutations that marks the pre-leukemia clone. For instance, the VAF for NPM1c, which might be acquired after the first mutation, varied in the 14-56% range. 22 Mutations in TET2 and IDH2 are believed to be initiating leukemogenic events in leukemia.
22,31 Nevertheless, we observed significant variation in engraftment of IDH2 and TET2 alleles post engraftment. Currently, IDH1/2 inhibitors are being studies in clinical trials. 35 We also detected IDH2 R140Q/W mutation frequency in 4-26% range in three PT samples, which does not support that that these mutations are initiating, Supplementary Table 6. Our data suggest that using PDX models for studying IDH1/2 or TET2 mutations might be risky and ought to include testing SVAF in all the mice. In 18 of 30 genes, we observed similar SVAF values in PT and PDX samples; these include likely founding mutations in DNMT3A, RUNX1 and NOTCH. At the same time, the SVAF in 12 genes have divergent values between PT and PDX samples. This might happen because these mutations are sub-clonal and influence engraftment in mice. Therefore, we conclude that PDX models will be useful for studying genomic alterations that are either known founding mutations in leukemia or do not influence engraftment. The use of PDX samples might be less informative for alleles such as PTEN or TP53, which engraft at very different frequencies in mice as compared with the PT samples. It is important to note, if SVAF is consistently increased in frequency, such as NPM1c, the PDX models might still be useful for studying the allele but this characteristic needs to be considered in any experimental interpretation.
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